Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?

Basit Öğe Kaydı
dc.authoridBaysal, Mehmet/0000-0001-7681-4623;
dc.authorwosidBaysal, Mehmet/E-9111-2018
dc.authorwosidUyanik, Mehmet/AAD-7345-2020
dc.contributor.authorUyanik, Mehmet Sevki
dc.contributor.authorBaysal, Mehmet
dc.contributor.authorPamuk, Gulsum Emel
dc.contributor.authorMaden, Muhammet
dc.contributor.authorAkker, Mustafa
dc.contributor.authorUmit, Elif Gulsum
dc.contributor.authorDemir, Muzaffer
dc.date.accessioned2024-06-12T10:56:31Z
dc.date.available2024-06-12T10:56:31Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe most common genetic disorder in Philadelphia negative chronic myeloproliferative neoplasms is the JAK2-V617F mutation. In the present study, we aimed to determine risk factors for thrombosis in patients with essential thrombocytosis and polycythemia vera. We screened the medical records of 101 patients. Risk factors which may predict thrombosis were recorded. Venous thrombosis (VT) before diagnosis was significantly higher in JAK2 positive patients. VT after diagnosis was similar in JAK2 positive and negative groups, and was significantly higher in elderly patients. Treatment places importance on the JAK2 mutation under unmodifiable cardiovascular risk factors such as advanced age after diagnosis.en_US
dc.identifier.doi10.1007/s12288-015-0578-2
dc.identifier.endpage267en_US
dc.identifier.issn0971-4502
dc.identifier.issn0974-0449
dc.identifier.issue3en_US
dc.identifier.pmid27429517en_US
dc.identifier.scopus2-s2.0-84939611636en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage262en_US
dc.identifier.urihttps://doi.org/10.1007/s12288-015-0578-2
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19807
dc.identifier.volume32en_US
dc.identifier.wosWOS:000378994200004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Indiaen_US
dc.relation.ispartofIndian Journal Of Hematology And Blood Transfusionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Myeloproliferative Neoplasmsen_US
dc.subjectJAK2 Mutationen_US
dc.subjectAllele Burdenen_US
dc.subjectThrombosisen_US
dc.subjectJak2 V617f Mutationen_US
dc.subjectWorld-Health-Organizationen_US
dc.subjectEssential Thrombocythemiaen_US
dc.subjectPolycythemia-Veraen_US
dc.subjectHigh-Risken_US
dc.subjectAllele Burdenen_US
dc.subjectHydroxyureaen_US
dc.subjectDiseaseen_US
dc.subjectTransformationen_US
dc.subjectJak2(V617f)en_US
dc.titleIs JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu